Stocktoria
Arcadia Biosciences, Inc. RKDA
Nasdaq · XNAS · stock · Crude Petroleum & Natural Gas · website · IPO 2015-05-15
Arcadia Biosciences, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -51.5% | -72.3% | -137.0% | -188.8% | -524.0% |
| Net margin | -48.1% | -139.5% | -313.9% | -207.3% | -216.2% |
| FCF margin | -96.7% | -191.1% | -343.5% | -189.4% | -396.4% |
| Return on assets | -35.7% | -52.1% | -71.0% | -53.2% | -33.4% |
| Return on equity | -56.5% | -113.1% | -108.9% | -73.1% | -47.0% |
| Debt / equity | — | — | — | — | 0.00× |
| Current ratio | 3.09 | 3.61 | 4.17 | 6.03 | 7.02 |
| Revenue growth | -3.7% | 13.3% | -40.0% | 9.4% | -15.6% |
Source: SEC EDGAR filings · CIK 0001469443 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.